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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease which mainly affects synovial joints and leads to damage of 
articular cartilage and ankylosis of joints. The effect of various drug interventions like the methotrexate, dipyridamole and ATP 
alone and in combination on RA were studied. RA was introduced with the help of Freund ’s adjuvant (0.5ml/200gms wistar rat) 
in  6  Separate Wistar rat groups. Freund ’s complete adjuvant (FCA) is the combination of mineral oil, an emulsifier mannide 
monooleate with 1mg/ml heat killed dry mycobacterium tuberculosis H37Ra. The mycobacterium stimulate the immune system 
and enhance the immune response. On 11th day after FCA the various animals groups were treated with drug interventions 
and after 10 days of treatment the paw edema of the respective rats were assessed by a mercury displacement 
plethysmograph (INCO Corp., India). During these studies the changes in paw edema by drug treatment of animals were 
analyzed. The results of this study are discussed in this article.  
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Rheumatoid arthritis (RA) is a chronic, autoimmune, 
inflammatory disorder of unknown aetiology that is 
characterized by symmetric synovitis and the 
propensity to cause joint destruction, disability and 
premature death. Disease-modifying anti-rheumatic 
drugs (DMARDs) slow the natural course of the 
disease, reduce joint damage and pain, and retard loss 
of function and disability. Treatment plays a key role in 
controlling the inflammation of rheumatoid arthritis and 
minimizing joint damage. Treatment usually entails a 
combination of drug therapy and other non-drug 
therapies. The levels of pro-inflammatory cytokines 
such as tumour necrosis factor-alpha (TNF-α), 
interleukin-1- (IL1-) and interleukin-6 (IL-6) are 
increased in arthritic joints (1), and these cytokines 
have been implicated in the joint destruction and tissue 
dysfunction seen in rheumatoid arthritis (2).  
The advocation of low dose methotrexate (MTX) is 
the most widely used anti-rheumatic drug and it is the 
‘gold standard’ against which other systemic 
medications are compared (3). . It has been suggested 
that at least part of the anti-inflammatory effects of the 
disease modifying anti-rheumatoid drugs methotrexate 
and sulphasalazine may be attributable to the release 
of the endogenous nucleoside adenosine by these 
drugs (4). It has as its target the enzyme dihydrofolate 
reductase, which is required for reduction of  
dihydrofolate to tetrahydrofolate (5). Adenosine, an 
additional active metabolite of MTX has been found to 
be potent anti-inflammatory effects, and earlier studies 
strongly support the notion that the potent anti-
inflammatory effect via suppression of inflammatory 
cytokines such as tumour necrosis factor (TNF)-alpha, 
interleukin-6, or macrophage inhibitory protein-1 alpha. 
It was further found that the anti-inflammatory effect of 
adenosine is mediated via A2A and the A3 adenosine 
receptors.  
The highly selective A3 adenosine receptor (A3AR) 
agonist 1B-MECA had an anti-inflammatory effect in 
collagen-induced arthritis in DBA1 mice and adjuvant-
induced arthritis (AIA) in rats. Adenosine is increasingly 
regarded as an important endogenous regulator of 
inflammatory processes. All the adenosine receptors 
currently recognised—A1, A2A, A2B and A3 can 
modify the release of inflammatory mediators or 
reactive oxygen species from immune-competent cells 
(6, 7). Most attention has been devoted to the A2 
receptors, with the A2A subtype being shown to 
decrease the secretion of TNF-alpha (8, 9) and IL-12 
(10,11) as well as suppressing the mitochondrial 
respiratory burst (12, 13). There is also evidence that 
similar activity may be shown by A2B receptors (14, 15) 
and A3 receptors (16, 17), while A1 receptors can 
promote the release of some cytokines (18) but 
suppress IL-6 secretion. The concept of a key role for 
adenosine receptors in inflammatory processes is 
supported by the up-regulation, especially of A2A and 
A2B receptors, that occurs in activated monocytes and 
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macrophages. Dipyridamole is a widely established 
drug for the treatment of angina pectoris and 
cerebrovascular disease. Its main mechanism of action 
is to inhibit the cellular uptake and metabolism of 
adenosine, with resulting vasodilatory and anti-
aggregatory effects. On the other hand, ATP is also 
found to be converted to adenosine  and may have 
prominent roles endogenously (19). We have now 
investigated the hypothesis that an increase in 
adenosine levels in patients, induced by chronic 
treatment with dipyridamole, may in turn lead to a 
reduction in pro-inflammatory cytokine release, and 
could alleviate the symptoms of rheumatoid arthritis. 
This study was hitherto conducted to ascertain the anti-
arthritic effect of dipyridamole and ATP and synergistic 
effect with methotrexate in adjuvant induced arthritis in 
albino Wistar rats. 
Materials and Methods 
Drugs  
Dipyridamole and ATP were obtained from Sigma 
chemical company (USA). Dipyridamole was dissolved 
in 0.1 N HCl  and ATP was dissolved in sterile water 
before using it for injection. Methotrexate and water for 
injection was obtained from the CMC pharmacy, 
Vellore. 
Test animals 
Wistar Lewis rats of either sex weighing around 175 
to 225 gms were used in the studies. Animals were 
housed in cages under standard lab conditions (12:12 
hr light dark cycle at 25 ± 5 degree C). The rats were 
fed with commercial rat diet and water ad libitum and 
were divided in to 6 groups, containing 6 animals in 
each group. The ethical guidelines for the involvement 
of the animals used in experiments were followed in all 
the tests. 
Induction of arthritis  
Arthritis was induced by a modified method 
described earlier (20). Arthritis was induced by injecting 
0.5 ml Freund’s complete adjuvant (FCA) containing 
1mg/ml of dry heat killed Mycobacterium butyricum of 
sterile paraffin oil in to plantar surface of right hind foot 
of all the animals. 
Experimental design 
Animals were divided in to 6 groups of  6 rats in 
each group. On the 11nth day after injecting FCA, the 
animals in the various groups received the respective 
drugs as follows:- Group 1 received saline 0.5 ml of 
0.9% NaCl and served as the control. Group 2 received 
MTX at a dose of 0.2 mg/kg on alternate days for a 
total period of 10 days. Group 3  received Dipyridamole 
at a dose of 10mg/kg for 10 days. Group 4 received 
ATP at a dose of 0.75 mg/kg for a period of 10 days. 
Group 5 received MTX 0.2mg/kg on alternate days 
along with Dipyridamole 10 mg/kg daily for 10 days. 
Group 6 received MTX 0.2 mg/kg on alternate 
days ,along with ATP 0.75 mg/kg daily for a total period 
of 10 days. After 10 days of treatment the paw edema 
of the respective rats were assessed by a mercury 
displacement plethysmograph (INCO Corp., India). The 
percentage inhibition of paw edema was calculated 
using the formula  1-Vt/Vc X100. Where by paw 
volume before arthritis(Vt) –paw volume after 
intervention(Vc)/ paw volume before arthritis(Vt) X 100 
Statistical analysis 
 The statistical analysis was conducted for control 
and test group of animals and comparisons were done 
between the control and test groups containing n=6 
number of animals. The statistical tests applied were 
the Wilcoxon signed ranks test and Man Whitney test 
and it was used for the analyses of the data. P<0.05 
were considered to be statistically significant.  
Results 
The results of this study are shown in Figure 1 and 
Table 1. Treatment of different animal groups (n=6) 
with dipyridamole (10mg/kg) and methotrexate 
(0.2mg/kg) caused substantial and significant 
improvement in paw edema caused by FCA injection. 
Similarly ATP (0.75mg/kg) was injected to the rats and 
it also caused a 36.11% reduction in paw edema. The 
improvement in paw edema was evaluated by a 
mercury displacement plethysmograph. The 
combination of methotrexate and dipyridamole 
produced a potentiated 46.39 % reduction in paw 
edema after treatment with these drugs for a duration 
for 10 days. However the combination of  methotrexate 
and ATP did not produce appreciable improvement as 
per our results and caused only a 9.72 % reduction in 
adjuvant arthritis.  
Discussion 
In our study, MTX produced a beneficial effect on 
FCA induced arthritis and this can be attributed to 
various factors. Amongst the first line of drugs available 
for rheumatoid arthritis, the foremost important is the 
drug MTX which is given at a low dose. It is now widely 
accepted that the mechanism of  action of MTX  in RA 
is  due to the inhibition of the enzyme AICAR 
transformylase by the MTX polyglutamates, which are 
formed after MTX is taken up by the inflammatory cells 
(21,22). Since AICARiboside directly inhibits ADA 
(adenosine deaminase which deaminates adenosine in 
to inosine) and AICAR inhibits AMP deaminase, the 
intracellular accumulation of AICAR could lead to 
release of adenosine and AMP (converted by 5’ 
nucleotidase to adenosine in the extracellular space) in 
to the extracellular space. It is this increase in 
adenosine concentration in the extracellular space 
which is responsible for the anti inflammatory effect 
seen in patients treated with MTX is proved in  
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experiments conducted by Cronstein et al (23,24). To 
further prove that  this adenosine released  was 
responsible for the anti-inflammatory effect,  was 
evident in other experiments where  agents like 
adenosine kinase inhibitors (25-27), sulfasalazine were 
used and were shown to have anti inflammatory effect 
as well by an adenosine dependent mechanism,in both 
in vitro and in vivo experiments. More support that MTX  
enhances adenosine release in humans, was provided 
by recent studies which showed that, children treated 
with MTX  for childhood leukaemia, had increased 
adenosine concentration in the cerebrospinal fluid. 
 
Similarly a reduction in paw edema was seen after 
treatment with dipyridamole and ATP to further the 
notion that adenosine is responsible for alleviating the 
symptoms of rheumatoid arthritis. ATP has been 
shown to be converted to adenosine endogenously and 
relieve the symptoms of arthritis (19), however it was 
less potent then dipyridamole and MTX. The anti-
inflammatory action caused by the drugs dipyridamole 
could be because of it’s reuptake inhibition of 
adenosine at the inflammation site. The study by 
German et al (28) showing that dipyridamole enhances 
plasma adenosine levels in human beings supports our 
claim that dipyridamole can cause increase in 
adenosine levels. And the concentrations of adenosine 
required to inhibit inflammatory cell function are similar 
to those observed in vivo (29)  and hence an increase 
in adenosine caused by dipyridamole can very well 
have an anti-inflammatory action. The adenosine thus 
released extracellularly, interacts with adenosine 
receptors on the cell surface and produces reduction in 
inflammation by suppression of inflammatory cytokines 
such as tumour necrosis factor (TNF)-alpha, 
interleukin-6 (30). Of particular interest is the 
interaction of adenosine on A2a receptor on stimulated 
neutrophils, that leads to inhibition of release of toxic 
oxygen metabolites, and adhesion to a variety of 
different cell types, and suppresses neutrophil 
mediated injury both in vitro and in vivo (31,32). With 
the above evidence, we also observed whether the 
adenosine reuptake-inhibitory action of dipyridamole 
would be sufficient to cause an anti inflammatory action 
in the above experiment, and similarly whether the 
adenosine released from the metabolism of ATP would 
have any anti inflammatory action as well. Our results 
portray that dipyridamole and methotrexate treatment 
per se significantly attenuated the paw edema. These 
results are novel and interesting. We also tried to 
evaluate, whether combining the drugs dipyridamole 
with methotrexate had any synergistic effect, on the 
basis that the adenosine released from MTX and 
adenosine reuptake inhibition by dipyridamole, 
increased the extracellular concentration of adenosine 
and this could lead to an enhanced anti inflammatory 
effect in what can be described a possible drug 
synergism. Our results thus confirm a salient role for 
dipyridamole and methotrexate combination in 
alleviating the paw edema induced by FCA. 
 
 
Figure 1: Figure 1 illustrates the bar graphs depicting the effects before and after injections of dipyridamole (10mg/kg), 
methotrexate (0.2mg/kg) and ATP (0.75mg/kg) on Freund’s complete adjuvant induced  paw edema in albino rats. The values 
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Table 1: Table 1 shows the effect of dipyridamole (10mg/kg), methotrexate (0.2mg/kg) and ATP (0.75mg/kg) on paw edema induced 
by Freund’s complete adjuvant injection. The percentage change from control group (saline treated) is compared with treated group and 
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